Ait-Aissa Karima, Leng Linette N, Lindsey Nathanial R, Guo Xutong, Juhr Denise, Koval Olha M, Grumbach Isabella M
Abboud Cardiovascular Research Center, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States.
Department of Biomedical Sciences, Dental College of Medicine, Lincoln Memorial University, Knoxville, TN, United States.
Front Cardiovasc Med. 2023 Jun 19;10:1133315. doi: 10.3389/fcvm.2023.1133315. eCollection 2023.
The incidental use of statins during radiation therapy has been associated with a reduced long-term risk of developing atherosclerotic cardiovascular disease. However, the mechanisms by which statins protect the vasculature from irradiation injury remain poorly understood.
Identify the mechanisms by which the hydrophilic and lipophilic statins pravastatin and atorvastatin preserve endothelial function after irradiation.
Cultured human coronary and umbilical vein endothelial cells irradiated with 4 Gy and mice subjected to 12 Gy head-and-neck irradiation were pretreated with statins and tested for endothelial dysfunction, nitric oxide production, oxidative stress, and various mitochondrial phenotypes at 24 and 240 h after irradiation.
Both pravastatin (hydrophilic) and atorvastatin (lipophilic) were sufficient to prevent the loss of endothelium-dependent relaxation of arteries after head-and-neck irradiation, preserve the production of nitric oxide by endothelial cells, and suppress the cytosolic reactive oxidative stress associated with irradiation. However, only pravastatin inhibited irradiation-induced production of mitochondrial superoxide; damage to the mitochondrial DNA; loss of electron transport chain activity; and expression of inflammatory markers.
Our findings reveal some mechanistic underpinnings of the vasoprotective effects of statins after irradiation. Whereas both pravastatin and atorvastatin can shield from endothelial dysfunction after irradiation, pravastatin additionally suppresses mitochondrial injury and inflammatory responses involving mitochondria. Clinical follow-up studies will be necessary to determine whether hydrophilic statins are more effective than their lipophilic counterparts in reducing the risk of cardiovascular disease in patients undergoing radiation therapy.
放疗期间偶然使用他汀类药物与降低动脉粥样硬化性心血管疾病的长期风险有关。然而,他汀类药物保护血管免受辐射损伤的机制仍知之甚少。
确定亲水性和脂溶性他汀类药物普伐他汀和阿托伐他汀在辐射后维持内皮功能的机制。
用4 Gy照射培养的人冠状动脉和脐静脉内皮细胞,并对接受12 Gy头颈部照射的小鼠进行他汀类药物预处理,在照射后24小时和240小时检测内皮功能障碍、一氧化氮生成、氧化应激和各种线粒体表型。
普伐他汀(亲水性)和阿托伐他汀(脂溶性)均足以预防头颈部照射后动脉内皮依赖性舒张功能的丧失,维持内皮细胞一氧化氮的生成,并抑制与照射相关的胞质活性氧化应激。然而,只有普伐他汀抑制照射诱导的线粒体超氧化物生成、线粒体DNA损伤、电子传递链活性丧失以及炎症标志物的表达。
我们的研究结果揭示了他汀类药物在辐射后血管保护作用的一些机制基础。普伐他汀和阿托伐他汀均可防止照射后内皮功能障碍,而普伐他汀还可抑制线粒体损伤和涉及线粒体的炎症反应。有必要进行临床随访研究,以确定亲水性他汀类药物在降低放疗患者心血管疾病风险方面是否比其脂溶性同类药物更有效。